ArticleCancers2022
Proposal of New Safety Limits for In Vivo Experiments of Magnetic Hyperthermia Antitumor Therapy.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Magnetically responsive electrospun fibers as programmable bioactive scaffolds: From formulation design to magnetically triggered therapy and regeneration.Bioactive materials · 2027Review
- Functional Repurposing of Magnetic Nanoparticle-Assisted Hyperthermia for Immune Cell Labelling and Tracking.Small methods · 2026Article
- Magnetothermally Responsive Mesoporous Silica Nanocarriers: Materials Design, Thermoresponsive Gates and Controlled Drug Release.Nanomaterials (Basel, Switzerland) · 2026Review
- Synergistic photothermal and magnetothermal heat generation with Sc-doped iron oxide nanoflakes: a platform for potential bimodal tumor therapy.Nano convergence · 2026Article
- In Vitro Antitumor Effects of Melittin Attached to FeMolecules (Basel, Switzerland) · 2026Article
- Magnetic Fields in Cancer Therapy: Mechanistic Insights, Signaling Pathways, and Evidence from Clinical and In Vitro Studies.Pharmaceutics · 2026Review
- Tunable PVA-Alginate/FeACS omega · 2026Article
- Spatiotemporal cancer controlNanomedicine (London, England) · 2026Review
- Targeting brain tumours with precision: advances in magnetic nanoparticle therapy.Nanoscale advances · 2026Review
- Article
- A Theoretical Framework for Ligand-Functionalised Magnetic Lipid Nanoparticles in Glioblastoma Therapy.Cancers · 2025Review
- Radio-magnetic dual-functional microspheres for magnetic hyperthermia therapy combined with radioembolization of hepatocellular carcinoma.Materials today. Bio · 2025Article
- Thermo-Magnetic Induction of Pro-Inflammatory Microglia: A Lipid-Based Nanovector Strategy for Glioblastoma Immunotherapy.ACS applied materials & interfaces · 2025Article
- Magnetic Hyperthermia with Iron Oxide Nanoparticles: From Toxicity Challenges to Cancer Applications.Nanomaterials (Basel, Switzerland) · 2025Review
- Magnetic activation of spherical nucleic acids enables the remote control of synthetic cells.Nature chemistry · 2025Article
- Comparative Influence of Dendron and Dicarboxylate Coatings on the Hyperthermia Performances of Cubic and Spherical Magnetic Nanoparticles.International journal of molecular sciences · 2025Article
- Localized brain stimulation with mild magnetic hyperthermia promotes microglia activity towards reactive and autophagic phenotypes in vivo.Scientific reports · 2025Article
- Nanomedicine Strategies in the Management of Inflammatory Bowel Disease and Colorectal Cancer.International journal of molecular sciences · 2025Review
- Simulation-Based Design and Machine Learning Optimization of a Novel Liquid Cooling System for Radio Frequency Coils in Magnetic Hyperthermia.Bioengineering (Basel, Switzerland) · 2025Article
- Evaluating Manganese-Doped Magnetic Nanoflowers for Biocompatibility and In Vitro Magnetic Hyperthermia Efficacy.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLately, major advances in crucial aspects of magnetic hyperthermia (MH) therapy have been made (nanoparticle synthesis, biosafety, etc.). However, there is one key point still lacking improvement: the magnetic field-frequency product (
methodsDifferent combinations of field frequency and intensity exceeding the Atkinson-Brezovich limit (591-920 kHz, and 10.3-18 kA/m) have been applied for 21 min to WAG/RijHsd male rats, randomly distributed to groups of 12 animals; half of them were sacrificed after 12 h, and the others 10 days later. Biochemical serum analyses were performed to assess the general, hepatic, renal and/or pancreatic function.
resultsMH raised liver temperature to 42.8 ± 0.4 °C. Although in five of the groups the exposure was relatively well tolerated, in the two of highest frequency (928 kHz) and intensity (18 kA/m), more than 50% of the animals died. A striking elevation in liver and systemic markers was observed after 12 h in the surviving animals, independently of the frequency and intensity used. Ten days later, liver markers were almost recovered in all of the animals. However, in those groups exposed to 591 kHz and 16 kA/m, and 700 kHz and 13.7 kA/m systemic markers remained altered.
conclusionsExceeding the Atkinson-Brezovich limit up to 9.59 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.